{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:57:37Z","timestamp":1791046657600,"version":"4.1.0"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Hypertension is associated with elevated mortality rates among individuals on maintenance hemodialysis (MHD). However, there is limited information regarding the efficacy and safety of sacubitril-valsartan (SV) in MHD patients suffering from hypertension. Consequently, this study aims to evaluate the efficacy and safety of SV in this specific patient population.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We retrospectively reviewed the data of MHD patients with hypertension who were receiving SV treatment at our hospital from January 1, 2023 to June 30, 2024. The SV dose ranged from 50\u2009mg twice daily to 200\u2009mg twice daily. Blood pressure measurements were compared at baseline and during follow-up intervals to assess therapeutic efficacy. Safety evaluations included comprehensive monitoring of treatment-emergent adverse events throughout the observation period.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 64 MHD patients hypertension (mean age\u2009=\u200954.11 years; male proportion\u2009=\u200973.4%) were ultimately included in the study. After three months of treatment with SV, the mean reductions in systolic blood pressure, diastolic blood pressure, and pulse pressure were 21.06\u2009\u00b1\u200915.82 mmHg (P\u2009&lt;\u20090.001), 8.41\u2009\u00b1\u200913.09 mmHg (P\u2009&lt;\u20090.001), and 12.65\u2009\u00b1\u200913.17 mmHg (P\u2009&lt;\u20090.001), respectively. With respect to safety, new-onset intradialytic hypotension was observed in three patients. The study also included twelve patients with hyperkalemia. Importantly, no patients reported experiencing cough, angioedema, or abnormal liver biochemistry. Among the 64 subjects, none required a dose reduction or discontinuation of SV due to these adverse effects.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In MHD patients with hypertension, SV demonstrates a preliminary ability to lower blood pressure and appears safe. Further prospective randomized studies are warranted to validate our findings.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0330038","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T17:43:44Z","timestamp":1757007824000},"page":"e0330038","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of sacubitril-valsartan in Maintenance Hemodialysis patients with hypertension:A retrospective study"],"prefix":"10.1371","volume":"20","author":[{"given":"Lili","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lupin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bayi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hejun","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0394-902X","authenticated-orcid":true,"given":"Shaofa","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"pone.0330038.ref001","doi-asserted-by":"crossref","DOI":"10.1053\/j.ajkd.2010.10.007","article-title":"US Renal Data System 2010 Annual Data Report","volume":"57","author":"AJ Collins","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"pone.0330038.ref002","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1681\/ASN.0000000000000315","article-title":"Resistant Hypertension in Dialysis: Epidemiology, Diagnosis, and Management","volume":"35","author":"PI Georgianos","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"pone.0330038.ref003","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1001\/jamainternmed.2017.4377","article-title":"Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5","volume":"177","author":"R Malhotra","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"16","key":"pone.0330038.ref004","article-title":"Effect of Blood Pressure Control on Long-Term Risk of End-Stage Renal Disease and Death Among Subgroups of Patients With Chronic Kidney Disease","volume":"8","author":"E Ku","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"pone.0330038.ref005","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1161\/HYPERTENSIONAHA.119.12697","article-title":"Mortality Outcomes With Intensive Blood Pressure Targets in Chronic Kidney Disease Patients","volume":"73","author":"R Aggarwal","year":"2019","journal-title":"Hypertension"},{"issue":"11","key":"pone.0330038.ref006","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"JJV McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0330038.ref007","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41440-021-00706-1","article-title":"Angiotensin receptor-neprilysin inhibitors: Comprehensive review and implications in hypertension treatment","volume":"44","author":"K Yamamoto","year":"2021","journal-title":"Hypertens Res"},{"issue":"4","key":"pone.0330038.ref008","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/HYPERTENSIONAHA.113.02002","article-title":"Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study","volume":"63","author":"K Kario","year":"2014","journal-title":"Hypertension"},{"issue":"1","key":"pone.0330038.ref009","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/jch.13153","article-title":"Efficacy and safety of sacubitril\/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study","volume":"20","author":"DG Cheung","year":"2018","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"4","key":"pone.0330038.ref010","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jjcc.2019.03.010","article-title":"Sacubitril\/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation","volume":"74","author":"H-Y Chang","year":"2019","journal-title":"Journal of Cardiology"},{"issue":"3","key":"pone.0330038.ref011","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/ehf2.12659","article-title":"Sacubitril\/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease","volume":"7","author":"S Lee","year":"2020","journal-title":"ESC Heart Fail"},{"key":"pone.0330038.ref012","doi-asserted-by":"crossref","first-page":"657067","DOI":"10.3389\/fmed.2021.657067","article-title":"Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis","volume":"8","author":"S Fu","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"pone.0330038.ref013","doi-asserted-by":"crossref","first-page":"2222841","DOI":"10.1080\/0886022X.2023.2222841","article-title":"Effects of sacubitril-valsartan in patients undergoing maintenance dialysis","volume":"45","author":"Y Ding","year":"2023","journal-title":"Ren Fail"},{"issue":"20","key":"pone.0330038.ref014","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki","volume":"310","year":"2013","journal-title":"JAMA"},{"issue":"5","key":"pone.0330038.ref015","doi-asserted-by":"crossref","DOI":"10.1161\/HYP.0000000000000087","article-title":"Measurement of Blood Pressure in Humans: A Scientific Statement From the American Heart Association","volume":"73","author":"P Muntner","year":"2019","journal-title":"Hypertension"},{"issue":"6","key":"pone.0330038.ref016","doi-asserted-by":"crossref","DOI":"10.1161\/HYP.0000000000000230","article-title":"Hypertension in Patients Treated With In-Center Maintenance Hemodialysis: Current Evidence and Future Opportunities: A Scientific Statement From the American Heart Association","volume":"80","author":"N Bansal","year":"2023","journal-title":"Hypertension"},{"issue":"12","key":"pone.0330038.ref017","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.3760\/cma.j.issn.0366-6999.20130835","article-title":"Prevalence, awareness, treatment, and control of hypertension in the non-dialysis chronic kidney disease patients","volume":"126","author":"Y Zheng","year":"2013","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"pone.0330038.ref018","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.amjmed.2007.11.025","article-title":"Hypertension Awareness, Treatment, and Control in Chronic Kidney Disease","volume":"121","author":"PA Sarafidis","year":"2008","journal-title":"The American Journal of Medicine"},{"issue":"2","key":"pone.0330038.ref019","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/ki.2014.276","article-title":"Increased postdialysis systolic blood pressure is associated with extracellular overhydration in hemodialysis outpatients","volume":"87","author":"A Nongnuch","year":"2015","journal-title":"Kidney International"},{"issue":"2","key":"pone.0330038.ref020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0272-6386(96)90309-1","article-title":"Role of volume overload in dialysis-refractory hypertension","volume":"28","author":"S Fishbane","year":"1996","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"pone.0330038.ref021","first-page":"29","article-title":"Importance of volume factors in dialysis related hypertension","volume":"48","author":"RL Lins","year":"1997","journal-title":"Clin Nephrol"},{"issue":"6","key":"pone.0330038.ref022","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1681\/ASN.2019020117","article-title":"Arterial Stiffness in the Heart Disease of CKD","volume":"30","author":"L Zanoli","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"27","key":"pone.0330038.ref023","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJM199212313272704","article-title":"Sympathetic overactivity in patients with chronic renal failure","volume":"327","author":"RL Converse","year":"1992","journal-title":"N Engl J Med"},{"key":"pone.0330038.ref024","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000429274","article-title":"Significance of the renin-angiotensin system for blood pressure regulation in end-stage renal disease","volume":"41","author":"HJ Kornerup","year":"1984","journal-title":"Contrib Nephrol"},{"issue":"9668","key":"pone.0330038.ref025","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0140-6736(09)60212-9","article-title":"Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials","volume":"373","author":"HJL Heerspink","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"pone.0330038.ref026","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/ndt\/gfw433","article-title":"Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)","volume":"32","author":"PA Sarafidis","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"pone.0330038.ref027","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure","volume":"380","author":"EJ Velazquez","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0330038.ref028","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure","volume":"141","author":"SD Solomon","year":"2020","journal-title":"Circulation"},{"issue":"28","key":"pone.0330038.ref029","article-title":"Effect and safety of LCZ696 in the treatment of hypertension: A meta-analysis of 9 RCT studies","volume":"98","author":"Q Li","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"36","key":"pone.0330038.ref030","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1093\/eurheartj\/ehab499","article-title":"Sacubitril\u2013valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction","volume":"42","author":"AM Jackson","year":"2021","journal-title":"European Heart Journal"},{"issue":"8","key":"pone.0330038.ref031","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jchf.2017.04.012","article-title":"The Transition From Hypertension to Heart Failure: Contemporary Update","volume":"5","author":"FH Messerli","year":"2017","journal-title":"JACC Heart Fail"},{"issue":"3","key":"pone.0330038.ref032","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000519643","article-title":"Pharmacokinetics and Pharmacodynamics of Sacubitril\/Valsartan in Maintenance Hemodialysis Patients with Heart Failure","volume":"51","author":"Z Feng","year":"2022","journal-title":"Blood Purif"},{"issue":"6","key":"pone.0330038.ref033","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/ehf2.12544","article-title":"Sacubitril\/valsartan in heart failure and end-stage renal insufficiency","volume":"6","author":"A Heyse","year":"2019","journal-title":"ESC Heart Fail"},{"issue":"3","key":"pone.0330038.ref034","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/jch.14635","article-title":"Efficacy and safety of sacubitril\/valsartan after switching from azilsartan in hemodialysis patients with hypertension","volume":"25","author":"Y Iwashima","year":"2023","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"15","key":"pone.0330038.ref035","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of Sacubitril\/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease","volume":"138","author":"R Haynes","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"pone.0330038.ref036","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/jch.14422","article-title":"Effects of Sacubitril\/Valsartan on resistant hypertension and myocardial work in hemodialysis patients","volume":"24","author":"B Wang","year":"2022","journal-title":"J of Clinical Hypertension"},{"issue":"1","key":"pone.0330038.ref037","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10557-023-07481-w","article-title":"Sacubitril\/Valsartan in Dialysis Patients: Update on Current Perspectives","volume":"39","author":"L Spatola","year":"2023","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"pone.0330038.ref038","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/hdi.13150","article-title":"Incidence of hyperkalemia in anuric hemodialysis patients treated with sacubitril\/valsartan","volume":"28","author":"X Li","year":"2024","journal-title":"Hemodialysis International"},{"issue":"5","key":"pone.0330038.ref039","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41440-021-00819-7","article-title":"Efficacy of sacubitril\/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study","volume":"45","author":"H Rakugi","year":"2022","journal-title":"Hypertens Res"},{"issue":"2","key":"pone.0330038.ref040","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000110090","article-title":"Location not quantity of blood pressure measurements predicts mortality in hemodialysis patients","volume":"28","author":"R Agarwal","year":"2008","journal-title":"Am J Nephrol"},{"issue":"6","key":"pone.0330038.ref041","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.2215\/CJN.02250507","article-title":"Home blood pressures are of greater prognostic value than hemodialysis unit recordings","volume":"2","author":"P Alborzi","year":"2007","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T17:43:51Z","timestamp":1757007831000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330038"}},"subtitle":[],"editor":[{"given":"Hean Teik","family":"Ong,","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":41,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0330038","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]}}}